论文部分内容阅读
目的:探讨获得性肺炎患者诊断及预后判断中,血清降钙素原(PCT)与C-反应蛋白(CRP)的临床应用价值。方法:34例获得性肺炎患者(观察组)与34名健康者(对照组),抽取两组对象静脉血2ml,经凝固、离心处理后,采用快速半定量法测定血清PCT,采用免疫比浊法测定CRP。观察组患者治疗后5日再次测定PCT、CRP。结果:治疗前,观察组血清PCT、CRP水平均显著高于对照组,差异有统计学意义(P<0.01);经5日治疗后,观察组血清PCT、CRP水平均显著低于治疗前,差异有统计学意义(P<0.01)。结论:在获得性肺炎诊断中,血清降钙素原与CRP具有一定的应用价值,且可用于预后效果的判断,值得推广。
Objective: To investigate the clinical value of serum procalcitonin (PCT) and C-reactive protein (CRP) in the diagnosis and prognosis of patients with acquired pneumonia. Methods: 34 patients with acquired pneumonia (observation group) and 34 healthy subjects (control group) were enrolled in the study. Serum PCT was determined by rapid semi-quantitative analysis after coagulation and centrifugation. Determination of CRP. Patients in the observation group were again tested for PCT and CRP 5 days after treatment. Results: Before treatment, serum PCT and CRP levels in the observation group were significantly higher than those in the control group (P <0.01). After 5 days of treatment, serum PCT and CRP levels in the observation group were significantly lower than those before treatment, The difference was statistically significant (P <0.01). Conclusion: In the diagnosis of acquired pneumonia, serum procalcitonin and CRP have some application value, and can be used to judge the prognostic effect, which is worth promoting.